Enzymotec Ltd (ENZY) 15.00 $ENZY
Enzymotec Ltd. to Participate in the Canaccord Genuity 34th Annual Growth Conference
GlobeNewswire - Thu Jul 31, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec"
, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 8:30 a.m. ET in Boston, MA.
Enzymotec Ltd. to Report Second Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Thu Jul 24, 3:09PM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that it will release financial results for the second quarter ended June 30, 2014 on Tuesday, August 5, 2014, before the market opens. Following the release, the Company will host a conference call to discuss these results with additional comments and details. Participating on the call will be Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer.
Enzymotec Ltd. Announces Publication of Clinical Study Results on Crying Reduction Following Usage of INFAT(R) in Infants
GlobeNewswire - Mon Jul 07, 7:38AM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today on publication of its clinical study results evaluating the effect of INFAT usage on crying in healthy infants (link to the journal: http://www.biomedcentral.com/1471-2431/14/152).
Enzymotec Ltd. Reports Commercial Introduction of Its Innovative Omega PC(TM) Advanced Fish Oil Product
GlobeNewswire - Mon Jun 23, 7:47AM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today the launch of Omega PC(TM), a new, premium fish oil-based omega-3 product.
Enzymotec Ltd. to Present New Findings Regarding Positive Effects of INFAT(R) on Chinese Babies Stool and Behavior
GlobeNewswire - Thu Jun 05, 3:05PM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that results of its clinical trial on INFAT (structured fat ingredient for infant nutrition, marketed by Advanced Lipids, a joint venture of AAK and Enzymotec) will be presented at the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Conference on June 9-12, 2014 in Jerusalem, Israel (to read the full scientific abstract go to: http://journals.lww.com/jpgn/Documents/ESPGHA...tracts.pdf Page: 432).
Enzymotec Ltd. to Participate in the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Fri May 23, 7:44AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" , a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 11:00 a.m. ET in New York, NY.
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware.
Enzymotec Ltd. Provides Update on Patent Litigation With Neptune
GlobeNewswire - Tue Apr 01, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company" , a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that following a mediation process with Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT) ("Neptune" , in conjunction with litigation in the U.S. International Trade Commission ("ITC" , and based on latest developments regarding Neptune's patents in the U.S. Patent and Trademark Office ("USPTO" , it has decided that it will not continue its efforts to negotiate a final settlement agreement with Neptune.
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
CLIA Waiver for Abaxis' Lipid Profile Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 2:20PM CDT
Abaxis received the CLIA waiver status for capillary draw for cholesterol, high density cholesterol and triglycerides.
Balanced View on Hanger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:50PM CDT
We are impressed with the Hanger's higher revenues and EPS guidance riding on improvements in Patient Care segment.
Baxter Downgraded to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 11:10AM CDT
Baxter's operating margin dropped 280 basis points (bps) year over year to 21% in the quarter.
Neogen Meets Q3 Earnings Ests, Beats Rev - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 9:50AM CDT
Neogen reported flat year over year adjusted earnings per share of 18 cents for the third quarter of fiscal 2014, in line with the Zacks Consensus Estimate.
St. Jude Medical's Prodigy Neurostimulator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 3:00PM CDT
St. Jude Medical's Prodigy Chronic Pain System is based on neurostimulation therapy in addition to Burst Technology.
Enzymotec (ENZY) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 7:42AM CDT
Enzymotec (ENZY) is now in Oversold Territory
St. Jude Medical Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 11:50AM CDT
Over the last 30 days, St. Jude Medical saw one upward estimate revision for fiscal 2014 with no downward revision over the same time frame.
Enzymotec Ltd. to Participate in the Canaccord Genuity 34th Annual Growth Conference
GlobeNewswire - Thu Jul 31, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec"
, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 8:30 a.m. ET in Boston, MA. Enzymotec Ltd. to Report Second Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Thu Jul 24, 3:09PM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that it will release financial results for the second quarter ended June 30, 2014 on Tuesday, August 5, 2014, before the market opens. Following the release, the Company will host a conference call to discuss these results with additional comments and details. Participating on the call will be Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer.
Enzymotec Ltd. Announces Publication of Clinical Study Results on Crying Reduction Following Usage of INFAT(R) in Infants
GlobeNewswire - Mon Jul 07, 7:38AM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today on publication of its clinical study results evaluating the effect of INFAT usage on crying in healthy infants (link to the journal: http://www.biomedcentral.com/1471-2431/14/152).
Enzymotec Ltd. Reports Commercial Introduction of Its Innovative Omega PC(TM) Advanced Fish Oil Product
GlobeNewswire - Mon Jun 23, 7:47AM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today the launch of Omega PC(TM), a new, premium fish oil-based omega-3 product.
Enzymotec Ltd. to Present New Findings Regarding Positive Effects of INFAT(R) on Chinese Babies Stool and Behavior
GlobeNewswire - Thu Jun 05, 3:05PM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that results of its clinical trial on INFAT (structured fat ingredient for infant nutrition, marketed by Advanced Lipids, a joint venture of AAK and Enzymotec) will be presented at the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Conference on June 9-12, 2014 in Jerusalem, Israel (to read the full scientific abstract go to: http://journals.lww.com/jpgn/Documents/ESPGHA...tracts.pdf Page: 432).
Enzymotec Ltd. to Participate in the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Fri May 23, 7:44AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec"
, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 11:00 a.m. ET in New York, NY. Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware. Enzymotec Ltd. Provides Update on Patent Litigation With Neptune
GlobeNewswire - Tue Apr 01, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"
, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that following a mediation process with Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT) ("Neptune" , in conjunction with litigation in the U.S. International Trade Commission ("ITC" , and based on latest developments regarding Neptune's patents in the U.S. Patent and Trademark Office ("USPTO" , it has decided that it will not continue its efforts to negotiate a final settlement agreement with Neptune. Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
CLIA Waiver for Abaxis' Lipid Profile Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 2:20PM CDT
Abaxis received the CLIA waiver status for capillary draw for cholesterol, high density cholesterol and triglycerides.
Balanced View on Hanger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:50PM CDT
We are impressed with the Hanger's higher revenues and EPS guidance riding on improvements in Patient Care segment.
Baxter Downgraded to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 11:10AM CDT
Baxter's operating margin dropped 280 basis points (bps) year over year to 21% in the quarter.
Neogen Meets Q3 Earnings Ests, Beats Rev - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 9:50AM CDT
Neogen reported flat year over year adjusted earnings per share of 18 cents for the third quarter of fiscal 2014, in line with the Zacks Consensus Estimate.
St. Jude Medical's Prodigy Neurostimulator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 3:00PM CDT
St. Jude Medical's Prodigy Chronic Pain System is based on neurostimulation therapy in addition to Burst Technology.
Enzymotec (ENZY) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 7:42AM CDT
Enzymotec (ENZY) is now in Oversold Territory
St. Jude Medical Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 11:50AM CDT
Over the last 30 days, St. Jude Medical saw one upward estimate revision for fiscal 2014 with no downward revision over the same time frame.
